@techreport{oai:mie-u.repo.nii.ac.jp:00013890,
 author = {岩本, 卓也 and Iwamoto, Takuya and 奥田, 真弘 and OKUDA, masahiro},
 month = {May},
 note = {application/pdf, 本研究では、ICIの作用部位であるエフェクターT細胞、NK細胞の特性変化について、末梢血を試料として治療効果や副作用との関連性を評価した。ROC解析より、好中球数およびCD28陽性CD8陽性T細胞数は、non-PDの予測率がそれぞれ81.8%、72.7%であった。ICI治療早期における好中球数やCD28陽性CD8陽性T細胞は、ICI治療を予測するバイオマーカーとなる可能性がある。, This study was performed to investigate the association of host factors including peripheral blood cell characteristics with the PD-1/PD-L1 therapy. A total of 20 patients were enrolled. The number of patients administrated pembrolizumab, nivolumab, and atezolizumab was 12, 7 and 1, respectively. Twelve patients were diagnosed as progressive disease (PD), and 8 were non-PD. All 6 female patients were diagnosed as PD. In the blood sample obtained within 3 weeks from the immune therapy, significantly high CD28 positive CD8+ T lymphocyte counts and low neutrophil counts were observed in the non-PD patients compared with the PD patients. Meanwhile, the distribution of tumor PD-L1 levels, clinical stage of NSCLC, and other immune markers investigated in the non-PD patients were comparable with the PD patients. CD28 positive CD8+ T lymphocyte and neutrophil counts were considered to be possible biomarkers related to the efficacy of PD-1/PD-L1 therapy., 2016年度～2018年度科学研究費補助金(基盤研究(C))研究成果報告書, 16K08369},
 title = {免疫チェックポイント阻害薬のPK/PD評価系構築と個別化治療への応用},
 year = {2019},
 yomi = {イワモト, タクヤ and オクダ, マサヒロ}
}